PHARMACY'S lexicon has just expanded with a new term hitting the pages of Pharmacy Daily: "Cannaceuticals".
The term refers to pharmaceutical grade cannabis made under the conditions of good manufacturing process (GMP), and was coined by CannRx announcing its joint venture with iCAN: Israel-Cannabis at CannaTech, a medical cannabis conference in Tel Aviv.
Together, the companies will bring to market ican.sleep, the first advanced sleep cannabis formulation utilizing the CannTrap platform developed by CannRx.
"ican.sleep is the first Cannaceutical (GMP, pharmaceutical grade cannabis product) available to the tens of millions of adults suffering sleep disorders," the companies said, with a global launch planned after patient trials later this year.
The pharmaceutical grade delivery system is said to provide a stable, controlled dose of the cannabis formulation.
CannRx said it had developed highly accurate quantitative and qualitative analytical chemical assays as well as disease-specific bioassays to determine the activity of specific cannabinoids.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Mar 17